8-K: Xilio Therapeutics Inks $2.1 Billion Collaboration Deal with AbbVie, Bolsters Cash Runway

Xilio Therapeutics and AbbVie have entered into a collaboration and option agreement potentially worth up to $2.1 billion to develop novel tumor-activated immunotherapies.

Summary

• Xilio Therapeutics has entered into a collaboration, license, and option agreement with AbbVie to develop tumor-activated immunotherapies.
• The agreement includes up to four programs leveraging Xilio's tumor-activation technology.
• Xilio will receive $52 million upfront, comprising $42 million in cash and a $10 million equity investment at $2.30 per share.
• Xilio is eligible for up to $2.1 billion in additional contingent payments, including program nomination fees, option extension fees, option fees, and development, regulatory, and sales-based milestones.
• Xilio is also eligible for tiered royalties ranging from high single digits on annual global net product sales for the Option Program and mid-single digits for the Collaboration Program.
• AbbVie has an option for up to three programs to discover, develop, and commercialize masked T cell engager molecules.
• Xilio is responsible for preclinical development up to IND-enabling studies for the Option Programs, while AbbVie handles further development and commercialization upon option exercise.
• For the Collaboration Program, Xilio handles preclinical development through lead generation, and AbbVie takes over further development and commercialization.
• Xilio anticipates its cash and cash equivalents, along with the upfront payment and proceeds from the AbbVie private placement, will fund operating expenses and capital expenditure requirements into the first quarter of 2026.
• Xilio is advancing three wholly-owned preclinical programs for masked T cell engagers targeting PSMA, CLDN18.2, and STEAP1.
• The company expects to nominate a development candidate for its PSMA program in Q3 2025 and submit an IND in Q1 2027.
• For the CLDN18.2 program, Xilio anticipates nominating a development candidate in Q4 2025 and submitting an IND in Q2 2027.
• The STEAP1 program is expected to have a development candidate nominated in the first half of 2026 and an IND submitted in the second half of 2027.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook due to the significant collaboration agreement with AbbVie, the potential for substantial future revenue, and the extension of the company's cash runway. The advancement of internal programs and the validation of the company's technology further contribute to the positive sentiment.

Positives

• The collaboration with AbbVie provides significant upfront funding and potential future revenue for Xilio.
• The deal validates Xilio's tumor-activation technology and platform.
• The collaboration allows Xilio to accelerate the development of its technology and expand into next-generation immunotherapies.
• The equity investment by AbbVie demonstrates confidence in Xilio's technology and potential.
• Xilio's cash runway is extended into Q1 2026, providing financial stability for ongoing research and development.
• Advancement of three internal masked T cell engager programs demonstrates Xilio's commitment to innovation.
• The potential for tiered royalties on product sales offers long-term revenue opportunities.

Negatives

• The majority of the potential $2.1 billion in payments are contingent upon achieving milestones, which are not guaranteed.
• The agreement is subject to termination under certain conditions, including AbbVie's decision not to exercise options or pay extension fees.
• Xilio is subject to exclusivity agreements with AbbVie regarding specific targets, which may limit its ability to pursue other partnerships.
• Anticipated milestones beyond the first quarter of 2026 are subject to obtaining sufficient additional capital.

Risks

• The success of the collaboration depends on the ability to discover, develop, and commercialize successful immunotherapies.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• Competition from other companies developing similar therapies could impact market share and revenue.
• Changes in market conditions or regulatory policies could affect the value of the agreement.
• Xilio's ability to maintain its collaboration and partnership agreements with Roche, Gilead and AbbVie is crucial.
• The company's reliance on its proprietary platform technology carries the risk that the technology may not perform as expected or may be superseded by other technologies.

Future Outlook

Xilio anticipates that its cash and cash equivalents, together with the upfront payment under the Agreement and the proceeds from the AbbVie Private Placement, will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2026. Anticipated milestones beyond the first quarter of 2026 are subject to obtaining sufficient additional capital.

Management Comments

• Theodora S. Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie, stated that the partnership with Xilio exemplifies AbbVie's commitment to expanding R&D efforts in oncology and investigating novel immunotherapy approaches.
• Uli Bialucha, Ph.D., chief scientific officer of Xilio, stated that the collaboration with AbbVie allows Xilio to accelerate the expansion of its technology to next-generation immunotherapies.
• Ren Russo, Pharm.D., president and chief executive officer of Xilio, stated that the company aims to lead the next wave of innovation in cancer immunotherapy by developing masked T cell engagers designed to improve tolerability through tumor-selective activation.

Industry Context

This announcement reflects the ongoing trend in the pharmaceutical industry towards collaborations and partnerships to develop novel cancer immunotherapies. Companies are increasingly seeking to combine their expertise and resources to accelerate the development of new treatments and improve patient outcomes. The focus on tumor-activated therapies highlights the industry's interest in developing more targeted and effective cancer treatments with fewer side effects.

Comparison to Industry Standards

• Deals of this size are not uncommon in the oncology space, particularly for novel technologies like Xilio's tumor-activation platform.
• Comparable deals include collaborations between major pharmaceutical companies and smaller biotech firms with innovative technologies.
• For example, similar deals in the T-cell engager space have seen upfront payments and potential milestone payments in the same order of magnitude.
• The tiered royalty structure is also standard in the industry, with the specific percentages depending on the stage of development and the market potential of the product.
• Companies like Amgen, Roche, and Novartis have also invested heavily in T-cell engager technology, making this a competitive but promising area.

Related Party Transactions

• The stock purchase agreement with AbbVie Inc. is a related party transaction.

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and potential for future revenue growth.
• Employees may benefit from increased job security and opportunities for advancement.
• Patients may benefit from the development of new and more effective cancer treatments.
• The collaboration could enhance Xilio's reputation and attract further investment.

Next Steps

• Xilio will file the Agreement, Stock Purchase Agreement, and Investor Rights Agreement with the SEC as exhibits to its Quarterly Report on Form 10-Q for the period ending March 31, 2025.
• Xilio will continue preclinical development of the Option Programs up to IND-enabling studies.
• AbbVie will have the option to exercise its rights for the Option Programs.
• Xilio will advance its three wholly-owned preclinical programs for masked T cell engagers.
• Xilio anticipates nominating a development candidate for its PSMA program in Q3 2025 and submitting an IND in Q1 2027.
• Xilio anticipates nominating a development candidate for its CLDN18.2 program in Q4 2025 and submitting an IND in Q2 2027.
• Xilio expects to nominate a development candidate for its STEAP1 program in the first half of 2026 and submit an IND in the second half of 2027.

Key Dates

Keywords

Xilio Therapeutics, AbbVie, Immunotherapy, T cell engager, Collaboration, License agreement, Oncology, Tumor-activated, Milestones, Royalties